Outcomes in COVID-19 colchicine studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
All studies 31% 12
17,762
Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 35% 11
17,449
Mortality 40% 10
17,373
Ventilation 32% 5
12,748
ICU admission 9% 2
299
Hospitalization 22% 2
4,588
Progression 55% 2
381
Recovery 20% 4
11,807
RCTs 14% 7
16,708
Peer-reviewed 46% 8
16,758
Late 31% 12
17,762
Colchicine for COVID-19 c19colchicine.com Nov 26, 2021
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón 35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
death
16/52
85/261
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
death
22/153
28/161
CT1
Dorward (RCT) -30%
1.30 [0.42-3.84]
hosp./death
6/156
4/133
Tau2 = 0.08; I2 = 73.9%
Late treatment 31%
0.69 [0.54-0.88]
1,256/8,681
1,419/9,081
31% improvement All studies 31%
0.69 [0.54-0.88]
1,256/8,681
1,419/9,081
31% improvement 12 colchicine COVID-19 studies c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.08; I2 = 73.9%; Z = 3.02 Effect extraction pre-specified
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón 35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
death
22/153
28/161
CT1
Dorward (RCT) -30%
1.30 [0.42-3.84]
hosp./death
6/156
4/133
Tau2 = 0.08; I2 = 76.3%
Late treatment 35%
0.65 [0.50-0.85]
1,240/8,629
1,334/8,820
35% improvement All studies 35%
0.65 [0.50-0.85]
1,240/8,629
1,334/8,820
35% improvement 11 colchicine COVID-19 studies after exclusions c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.08; I2 = 76.3%; Z = 3.12 Effect extraction pre-specified
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
0/36
2/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
122 (n)
140 (n)
Pinzón 35%
0.65 [0.34-1.21]
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
16/52
85/261
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
22/153
28/161
CT1
Tau2 = 0.17; I2 = 74.5%
Late treatment 40%
0.60 [0.42-0.86]
1,250/8,475
1,415/8,898
40% improvement All studies 40%
0.60 [0.42-0.86]
1,250/8,475
1,415/8,898
40% improvement 10 colchicine COVID-19 mortality results c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.17; I2 = 74.5%; Z = 2.82 Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 82%
0.18 [0.02-1.50]
1/55
5/50
Improvement, RR [CI] Treatment Control Sandhu 53%
0.47 [0.33-0.67]
16/34
68/68
Tardif (DB RCT) 47%
0.53 [0.25-1.09]
11/2,235
21/2,253
Recovery C.. (RCT) -18%
1.18 [0.99-1.40]
259/3,815
228/3,962
Gaitán-Dua.. (RCT) 15%
0.85 [0.68-1.06]
27/136
27/140
CT1
Tau2 = 0.25; I2 = 84.9%
Late treatment 32%
0.68 [0.40-1.15]
314/6,275
349/6,473
32% improvement All studies 32%
0.68 [0.40-1.15]
314/6,275
349/6,473
32% improvement 5 colchicine COVID-19 mechanical ventilation results c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.25; I2 = 84.9%; Z = 1.44 Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lopes (DB RCT) 50%
0.50 [0.10-2.56]
2/36
4/36
Improvement, RR [CI] Treatment Control Gaitán-Dua.. (RCT) 1%
0.99 [0.56-1.74]
19/113
18/114
CT1
Tau2 = 0.00; I2 = 0.0%
Late treatment 9%
0.91 [0.53-1.59]
21/149
22/150
9% improvement All studies 9%
0.91 [0.53-1.59]
21/149
22/150
9% improvement 2 colchicine COVID-19 ICU results c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 0.31 Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Improvement, RR [CI] Treatment Control Tardif (DB RCT) 20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Tau2 = 0.00; I2 = 0.0%
Late treatment 22%
0.78 [0.68-0.89]
101/2,285
128/2,303
22% improvement All studies 22%
0.78 [0.68-0.89]
101/2,285
128/2,303
22% improvement 2 colchicine COVID-19 hospitalization results c19colchicine.com Nov 26, 2021
Tau2 = 0.00; I2 = 0.0%; Z = 3.72
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Pinzón 35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
death
16/52
85/261
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
death
22/153
28/161
CT1
Dorward (RCT) -30%
1.30 [0.42-3.84]
hosp./death
6/156
4/133
Tau2 = 0.16; I2 = 71.9%
Late treatment 37%
0.63 [0.45-0.88]
1,256/8,631
1,419/9,031
37% improvement All studies 37%
0.63 [0.45-0.88]
1,256/8,631
1,419/9,031
37% improvement 11 colchicine COVID-19 serious outcomes c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.16; I2 = 71.9%; Z = 2.69 Effect extraction pre-specified
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Brunetti (PSM) 73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Improvement, RR [CI] Treatment Control Sandhu 42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Recovery C.. (RCT) -2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Dorward (RCT) 6%
0.94 [0.72-1.24]
no recov.
156 (n)
133 (n)
Tau2 = 0.07; I2 = 77.6%
Late treatment 20%
0.80 [0.58-1.09]
1,728/5,833
1,772/5,974
20% improvement All studies 20%
0.80 [0.58-1.09]
1,728/5,833
1,772/5,974
20% improvement 4 colchicine COVID-19 recovery results c19colchicine.com Nov 26, 2021
Tau2 = 0.07; I2 = 77.6%; Z = 1.40
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
death
22/153
28/161
CT1
Dorward (RCT) -30%
1.30 [0.42-3.84]
hosp./death
6/156
4/133
Tau2 = 0.03; I2 = 57.1%
Late treatment 14%
0.86 [0.69-1.06]
1,207/8,295
1,237/8,413
14% improvement All studies 14%
0.86 [0.69-1.06]
1,207/8,295
1,237/8,413
14% improvement 7 colchicine COVID-19 Randomized Controlled Trials c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.03; I2 = 57.1%; Z = 1.40 Effect extraction pre-specified
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
0/36
2/36
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
1,173/5,610
1,190/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
22/153
28/161
CT1
Tau2 = 0.02; I2 = 15.2%
Late treatment 8%
0.92 [0.72-1.17]
1,201/8,089
1,233/8,230
8% improvement All studies 8%
0.92 [0.72-1.17]
1,201/8,089
1,233/8,230
8% improvement 5 colchicine COVID-19 RCT mortality results c19colchicine.com Nov 26, 2021
1 CT: study uses combined treatment Tau2 = 0.02; I2 = 15.2%; Z = 0.69 Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
death
16/52
85/261
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Tau2 = 0.23; I2 = 79.0%
Late treatment 46%
0.54 [0.34-0.85]
1,214/8,177
1,364/8,581
46% improvement All studies 46%
0.54 [0.34-0.85]
1,214/8,177
1,364/8,581
46% improvement 8 colchicine COVID-19 peer reviewed trials c19colchicine.com Nov 26, 2021
Tau2 = 0.23; I2 = 79.0%; Z = 2.65
Effect extraction pre-specified
Favors colchicine
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI] Treatment Control Deftereos (RCT) 82%
0.18 [0.02-1.50]
ventilation
1/55
5/50
Deftereos (RCT) 87%
0.13 [0.01-0.97]
progression
1/55
7/50
Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Lopes (DB RCT) 50%
0.50 [0.10-2.56]
ICU
2/36
4/36
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Brunetti (PSM) 73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón 35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Sandhu 53%
0.47 [0.33-0.67]
ventilation
16/34
68/68
Sandhu 42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
death
16/52
85/261
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Tardif (DB RCT) 47%
0.53 [0.25-1.09]
ventilation
11/2,235
21/2,253
Tardif (DB RCT) 20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Recovery C.. (RCT) -18%
1.18 [0.99-1.40]
ventilation
259/3,815
228/3,962
Recovery C.. (RCT) -2%
1.02 [0.96-1.09]
int./death
1,344/5,342
1,343/5,469
Recovery C.. (RCT) -2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Gaitán-Dua.. (RCT) 19%
0.81 [0.48-1.35]
death
22/153
28/161
CT1
Gaitán-Dua.. (RCT) 15%
0.85 [0.68-1.06]
ventilation
27/136
27/140
CT1
Gaitán-Dua.. (RCT) 1%
0.99 [0.56-1.74]
ICU
19/113
18/114
CT1
Dorward (RCT) -30%
1.30 [0.42-3.84]
hosp./death
6/156
4/133
Dorward (RCT) 22%
0.78 [0.30-1.73]
hosp./death
6/156
119/1,145
Dorward (RCT) 6%
0.94 [0.79-1.11]
progression
102/156
83/120
Dorward (RCT) 6%
0.94 [0.72-1.24]
no recov.
156 (n)
133 (n)
colchicine COVID-19 outcomes c19colchicine.com Nov 26, 2021
Favors colchicine
Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
